Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Sidley Austin, Simpson Thacher, Norton Rose, White & Case, among others, all announced new corporate partners this week in ...

With private asset ETFs still awaiting regulatory approval, opportunistic issuers are continuing to crank out products that ...

Skilled nursing deals are plentiful, and private equity has a large role to play in their abundance, according to leaders at ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Baby Boomers are "the luckiest generation" in America and the most entitled in recent history, how did they get so lucky?

Health Affairs' Jeff Byers welcomes Senior Editor Kathleen Haddad back to the program to discuss two recent reports exploring the impacts of private equity on the US health care system.

With private-sector diversity, equity and inclusion policies in the government’s crosshairs, businesses are ditching ...

Foroughi and his two AppLovin co-founders had built the company in five years with just $4 million raised from angel investors, according to the press release that announced the deal. A nice payday ...

Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...

Private-equity executives entered 2025 with high hopes for a dealmaking recovery that is lifting payouts to fund investors ...

Record revenues from management fees and a brighter outlook for M&A in the year ahead helped private equity's Big Four close 2024 on a high note.